
Quarterly report 2024-Q1
added 05-16-2026
Motus GI Holdings Net Debt 2011-2026 | MOTS
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Motus GI Holdings
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -3.55 M | -9.21 M | -15.1 M | -12.6 M | -12.5 M | -18 M | -6.94 M | -11.6 M | 3.45 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.45 M | -18 M | -9.57 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Diagnostics research industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Enzo Biochem
ENZ
|
-51.3 M | - | -8.98 % | $ 14.8 K | ||
|
Centogene N.V.
CNTG
|
1.18 M | - | -6.23 % | $ 30.6 M | ||
|
Heska Corporation
HSKA
|
-153 M | - | - | $ 1.31 B | ||
|
Fulgent Genetics
FLGT
|
-53.3 M | $ 19.5 | 7.5 % | $ 600 M | ||
|
Celcuity
CELC
|
-28.1 M | $ 92.47 | 3.96 % | $ 4.32 B | ||
|
Akumin
AKU
|
1.21 B | - | -17.87 % | $ 25.9 M | ||
|
Co-Diagnostics
CODX
|
-10.6 M | $ 5.76 | 11.41 % | $ 7.66 M | ||
|
Castle Biosciences
CSTL
|
-106 M | $ 21.6 | 5.93 % | $ 626 M | ||
|
Aspira Women's Health
AWH
|
-512 K | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
-14.5 M | - | -61.36 % | $ 2.46 M | ||
|
Guardant Health
GH
|
1.15 B | $ 133.06 | 4.75 % | $ 16.7 B | ||
|
Biocept
BIOC
|
-11.2 M | - | -13.05 % | $ 7.29 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
-173 M | - | - | $ 562 M | ||
|
ICON Public Limited Company
ICLR
|
2.26 B | $ 152.8 | 6.18 % | $ 12 B | ||
|
CareDx, Inc
CDNA
|
-39.2 M | $ 23.12 | 3.63 % | $ 1.23 B | ||
|
Illumina
ILMN
|
-854 M | $ 168.06 | -1.68 % | $ 26 B | ||
|
Chembio Diagnostics
CEMI
|
-17.2 M | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
-3.13 M | - | - | $ 9.42 M | ||
|
Interpace Biosciences
IDXG
|
-1.32 M | $ 1.79 | 2.29 % | $ 7.92 M | ||
|
HTG Molecular Diagnostics
HTGM
|
-11.2 M | - | -20.0 % | $ 1.06 M | ||
|
Global Cord Blood Corporation
CO
|
-6.07 B | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
-5.38 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
-789 K | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
-1.35 B | - | 0.12 % | $ 80.1 M | ||
|
Mettler-Toledo International
MTD
|
2.06 B | - | - | $ 24.3 B | ||
|
DermTech
DMTK
|
-33.6 M | - | -11.32 % | $ 2.94 M | ||
|
Lantheus Holdings
LNTH
|
213 M | - | - | $ 6.94 B | ||
|
NeoGenomics
NEO
|
187 M | $ 11.31 | 11.54 % | $ 1.45 B | ||
|
Charles River Laboratories International
CRL
|
1.98 B | $ 185.79 | 3.29 % | $ 9.21 B | ||
|
Natera
NTRA
|
-942 M | $ 222.1 | 4.84 % | $ 30.4 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
769 M | - | - | $ 10.7 B | ||
|
Medpace Holdings
MEDP
|
-360 M | $ 458.69 | 1.75 % | $ 13.2 B | ||
|
Exact Sciences Corporation
EXAS
|
-916 M | - | - | $ 19.8 B | ||
|
National Research Corporation
NRC
|
71.3 M | $ 19.75 | 3.73 % | $ 442 M | ||
|
Myriad Genetics
MYGN
|
-22.8 M | $ 4.69 | 6.59 % | $ 434 M | ||
|
Personalis
PSNL
|
-117 M | $ 12.1 | 12.24 % | $ 1.08 B | ||
|
Koninklijke Philips N.V.
PHG
|
2.48 B | $ 25.99 | 2.52 % | $ 24.6 B | ||
|
Senseonics Holdings
SENS
|
-4.15 M | $ 7.01 | 4.32 % | $ 293 M | ||
|
QIAGEN N.V.
QGEN
|
1.31 B | - | - | $ 10.6 B | ||
|
Soleno Therapeutics
SLNO
|
-19.5 M | - | - | $ 2.69 B | ||
|
Biomerica
BMRA
|
-1.94 M | - | - | $ 4.94 M | ||
|
Laboratory Corporation of America Holdings
LH
|
4.74 B | $ 260.97 | 0.79 % | $ 21.7 B | ||
|
Twist Bioscience Corporation
TWST
|
-107 M | - | - | $ 4.42 B | ||
|
Thermo Fisher Scientific
TMO
|
29.6 B | $ 482.03 | 1.7 % | $ 182 B | ||
|
Trinity Biotech plc
TRIB
|
55.4 M | $ 0.68 | -2.4 % | $ 244 M | ||
|
Neogen Corporation
NEOG
|
751 M | $ 9.12 | 3.52 % | $ 1.98 B | ||
|
Quest Diagnostics Incorporated
DGX
|
4.92 B | $ 196.12 | 1.27 % | $ 21.8 B | ||
|
Invitae Corporation
NVTA
|
-239 M | - | - | $ 21.2 M | ||
|
Waters Corporation
WAT
|
391 M | $ 376.47 | -0.87 % | $ 22.4 B |